• info@icbcongress.com
• English
• Persian

• Login

Create Free Account

INTERNATIONAL CONGRESS OF

CancerGenetics

• Development of Hyaluronic acid (HA)-based nanocarriers for delivery of miRNAs in breast cancer therapy

• Fereshteh Rahdan,¹ Zeinab Chaharlashkar,² Dariush Rahdan,³ Sevda Mashhadi Jolfaei,⁴ Fatemeh Abedi,⁵ meysam yousefi,^6,*
  1. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  2. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  3. Department of Medical, Faculty of Medicine, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
  4. Department of Periodontics, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
  5. Clinical Research Development, Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
  6. Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  
  
  
• Introduction: Breast cancer is very common in the world and is considered as first rank deadly cancer in woman. In recent years, gene therapy based on miRNAs as important pathological regulators of cancer has been gained more attention for developing advanced therapeutics. However, direct administration of miRNAs has a very low and unrealistic effect due to low stability and reduced penetration along the cell membrane. High efficiency delivery carriers are required for targeted miRNA delivery. Hyaluronic acid (HA) is a polysaccharide and because of its natural affinity to bind to CD44 expressed on tumor cells surface it has been used in the delivery of miRNA and drugs. Also, HA has unique biological and chemical properties including biocompatibility and having multiple functional groups for chemical composition with polymers to be utilized in breast cancer targeting. This review discusses the recent progress and future prospects in HA-mediated delivery of miRNAs with significance in breast cancer therapy.
• Methods: Original articles published since 2008 on HA nanocarriers in the field of RNA carrier for breast cancer treatment were searched from Google Scholar, Scopus, and PubMed databases. Using these information, the application and properties of HA-based nanocarriers were discussed.
• Results: About 18 different microRNAs were tested to evaluate their efficacy and the safety in triple-negative mice models. Among all founded miR-based therapeutics, miR-21 was the most studies miRNA and miR-205a showed proper antitumor and antimetastatic effects. Recently, a hyaluronic acid (HA)-decorated polyethyleneimine poly (D, L-lactide-co-glycolide) (PEI-PLGA) nanoparticle system was developed, which enabled active targeted co-administration of miR-542-3p and doxorubicin (DOX) for Treatment of triple negative breast cancer (TNBC). HA/PEI-PLGA nanoparticles increased drug uptake in MDA-MB cells and miR-542-3p induced apoptosis in breast cancer cells through p53 activation. Moreover, in another study miR-34a was delivered in combination with DOX in TNBC by HA-chitosan nanoparticles.
• Conclusion: Regarding the biocompatibility and excellent targeting efficiency of HA mediated delivery of miRNAs in published breast cancer studies, the use of HA-based nanocarriers is highly recommended for future breast cancer therapies.
• Keywords: Hyaluronic acid (HA), delivery of miRNAs, breast cancer therapy